In the present study, we therefore assessed broad mutation profiles, EGFR methylation and expression as well as E-cadherin expression as predictive markers in 7 CRC cell lines treated by EGFR-targeted mAb in vitro as well as in a cohort of 25 clinically RAS wildtype CRC patients having been treated by EGFR-targeted therapy. Here, EGFR is linked to colorectal carcinoma.